These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29926245)

  • 1. Ranking Itraconazole Formulations Based on the Flux through Artificial Lipophilic Membrane.
    Tsinman K; Tsinman O; Lingamaneni R; Zhu S; Riebesehl B; Grandeury A; Juhnke M; Van Eerdenbrugh B
    Pharm Res; 2018 Jun; 35(8):161. PubMed ID: 29926245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
    Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.
    Thiry J; Kok MG; Collard L; Frère A; Krier F; Fillet M; Evrard B
    Eur J Pharm Sci; 2017 Mar; 99():1-8. PubMed ID: 27951411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of a suitable in vitro dissolution test for itraconazole-based solid dispersions.
    Thiry J; Broze G; Pestieau A; Tatton AS; Baumans F; Damblon C; Krier F; Evrard B
    Eur J Pharm Sci; 2016 Mar; 85():94-105. PubMed ID: 26850682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of spray dried ternary solid dispersions comprising itraconazole, soluplus and HPMCP: Effect of constituent compositions.
    Davis MT; Potter CB; Mohammadpour M; Albadarin AB; Walker GM
    Int J Pharm; 2017 Mar; 519(1-2):365-372. PubMed ID: 28131850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
    Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.
    DiNunzio JC; Miller DA; Yang W; McGinity JW; Williams RO
    Mol Pharm; 2008; 5(6):968-80. PubMed ID: 19434851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.
    Sim T; Lim C; Lee JW; Kim DW; Kim Y; Kim M; Choi S; Choi HG; Lee ES; Kim KS; Kang W; Oh KT
    J Pharm Pharmacol; 2017 Dec; 69(12):1707-1715. PubMed ID: 28872678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs.
    Yin X; Daintree LS; Ding S; Ledger DM; Wang B; Zhao W; Qi J; Wu W; Han J
    Drug Des Devel Ther; 2015; 9():2801-10. PubMed ID: 26060397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D; Chen H; Wan J; Xu H; Yang X
    Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hot-melt extrusion for enhanced delivery of drug particles.
    Miller DA; McConville JT; Yang W; Williams RO; McGinity JW
    J Pharm Sci; 2007 Feb; 96(2):361-76. PubMed ID: 17075869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of stability-enhanced ternary solid dispersions via combinations of HPMCP and Soluplus
    Albadarin AB; Potter CB; Davis MT; Iqbal J; Korde S; Pagire S; Paradkar A; Walker G
    Int J Pharm; 2017 Oct; 532(1):603-611. PubMed ID: 28923766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
    Sun W; Ni R; Zhang X; Li LC; Mao S
    Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
    Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
    Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved oral absorption profile of itraconazole in hypochlorhydria by self-micellizing solid dispersion approach.
    Kojo Y; Matsunaga S; Suzuki H; Sato H; Seto Y; Onoue S
    Eur J Pharm Sci; 2017 Jan; 97():55-61. PubMed ID: 27810562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers.
    Yang W; Tam J; Miller DA; Zhou J; McConville JT; Johnston KP; Williams RO
    Int J Pharm; 2008 Sep; 361(1-2):177-88. PubMed ID: 18556158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and characterization of biocompatible and stable I.V. itraconazole nanosuspensions stabilized by a new stabilizer polyethylene glycol-poly(β-Benzyl-l-aspartate) (PEG-PBLA).
    Zong L; Li X; Wang H; Cao Y; Yin L; Li M; Wei Z; Chen D; Pu X; Han J
    Int J Pharm; 2017 Oct; 531(1):108-117. PubMed ID: 28830781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
    Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
    Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous production of itraconazole-based solid dispersions by hot melt extrusion: Preformulation, optimization and design space determination.
    Thiry J; Lebrun P; Vinassa C; Adam M; Netchacovitch L; Ziemons E; Hubert P; Krier F; Evrard B
    Int J Pharm; 2016 Dec; 515(1-2):114-124. PubMed ID: 27720874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.
    Maincent JP; Najvar LK; Kirkpatrick WR; Huang S; Patterson TF; Wiederhold NP; Peters JI; Williams RO
    Drug Dev Ind Pharm; 2017 Feb; 43(2):264-274. PubMed ID: 27645428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.